** Dimerix DXB.AX surges as much as 58.33% to A$0.760, highest since September 9, 2020
** Stock marks biggest intraday pct gain since October 5, 2023
** Biotech firm announces exclusive license agreement with Amicus Therapeutics FOLD.O to commercialise its Phase 3 drug candidate, DMX-200, in the U.S.
** Says DMX-200 currently being developed to treat focal segmental glomerulosclerosis kidney disease
** Stock sees busiest session since October 6, 2023, with more than 31 mln shares traded - 18.3x the 30-day avg
** Last up 50%, DXB more than doubles YTD
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。